F. Binder-foucard, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

, Ovarian cancer, five-year stage-specific relative survival rates, J. Natl. Cancer Inst, vol.103, p.1287, 2004.

R. De-angelis, Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study, Lancet Oncol, vol.15, pp.23-34, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915077

C. Sun, The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis, PLoS ONE, vol.9, p.95285, 2014.

B. Gronlund, C. Høgdall, H. H. Hansen, and S. A. Engelholm, Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma, Cancer, vol.94, pp.1961-1967, 2002.

, StatBite Ovarian Cancer, Five-Year Stage-Specific Relative Survival Rates, 2004.

, JNCI J. Natl. Cancer Inst, vol.103, pp.1287-1287, 2011.

R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis, J. Clin. Oncol, vol.20, pp.1248-1259, 2002.

A. Elattar, A. Bryant, B. A. Winter-roach, M. Hatem, and R. Naik, Optimal primary surgical treatment for advanced epithelial ovarian cancer, Cochrane Database Syst. Rev, 2011.

J. M. Hall, Linkage of early-onset familial breast cancer to chromosome 17q21, Science, vol.250, pp.1684-1689, 1990.

A. R. Venkitaraman, Cancer suppression by the chromosome custodians, BRCA1 and BRCA2, Science, vol.343, pp.1470-1475, 2014.

A. G. Patel, J. N. Sarkaria, and S. H. Kaufmann, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombinationdeficient cells, Proc. Natl. Acad. Sci. U. S. A, vol.108, pp.3406-3411, 2011.

B. A. Werness, Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations, Hum. Pathol, vol.31, pp.1420-1424, 2000.

N. Mavaddat, Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE, JNCI J. Natl. Cancer Inst, vol.105, pp.812-822, 2013.

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.25, pp.1329-1333, 2007.

A. Antoniou, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am. J. Hum. Genet, vol.72, pp.1117-1130, 2003.

M. King, J. H. Marks, and J. B. Mandell, & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, vol.302, pp.643-646, 2003.

J. M. Lancaster, C. B. Powell, L. Chen, and D. L. Richardson, Society of Gynecologic, vol.83

, Oncology statement on risk assessment for inherited gynecologic cancer predispositions, Gynecol. Oncol, vol.136, pp.3-7, 2015.

B. T. Hennessy, Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer, J. Clin. Oncol, vol.28, pp.3570-3576, 2010.

K. P. Pennington, Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas, Clin. Cancer Res, vol.20, pp.764-775, 2014.

H. Farmer, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-921, 2005.

A. Ashworth and . Synthetic, Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair, J. Clin. Oncol, vol.26, pp.3785-3790, 2008.

J. Z. Press, Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities, BMC Cancer, vol.8, 2008.
DOI : 10.1186/1471-2407-8-17

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-8-17

J. Ledermann, Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer, N. Engl. J. Med, vol.366, pp.1382-1392, 2012.

J. A. Ledermann, Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Oncol, vol.17, pp.1579-1589, 2016.

M. R. Mirza, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N. Engl. J. Med, vol.375, pp.2154-2164, 2016.

E. M. Swisher, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial, Lancet Oncol, vol.18, pp.75-87, 2017.

D. S. Tan and S. B. Kaye, Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?, Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet, vol.8, pp.114-121, 2015.

Q. Zhong, H. Peng, X. Zhao, L. Zhang, and W. Hwang, Effects of BRCA1-and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis, Clin. Cancer Res, vol.21, pp.211-220, 2015.

K. Xu, S. Yang, and Y. Zhao, Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis, Oncotarget, vol.8, 2017.

K. L. Bolton, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, JAMA, vol.307, pp.382-390, 2012.

J. Boyd, Clinicopathologic features of BRCA-linked and sporadic ovarian cancer, JAMA, vol.283, pp.2260-2265, 2000.

A. Pauw and . De, Hereditary forms of ovarian cancer, Bull. Cancer, pp.453-462, 2012.

A. Melamed, Associations between residual disease and survival in epithelial ovarian cancer by histologic type, Gynecol. Oncol, vol.147, pp.250-256, 2017.
DOI : 10.1016/j.ygyno.2017.08.003

T. V. Gorodnova, High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation, Cancer Lett, vol.369, pp.363-367, 2015.

I. Vergote, Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer, Eur. J. Cancer, vol.47, pp.88-92, 2011.
DOI : 10.1016/s0959-8049(11)70152-6

V. Da-costa-miranda, Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness, Gynecol. Oncol, vol.132, pp.287-291, 2014.

E. Stoeckle, Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery, Ann. Surg. Oncol, vol.21, pp.629-636, 2014.

P. E. Colombo, Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer, Gynecol. Oncol, vol.135, pp.223-230, 2014.

, Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer (CHRONO) -NCT03579394, 2018.

P. M. Vencken, Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients, Ann. Oncol, vol.22, pp.1346-1352, 2011.

. Femmes-porteuses-d'une-mutation, . De, and . Ou-brca2, Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque-E-Cancer, Avril 2017. 63. Zwakman, N. et al. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer, J. Gynecol. Oncol, vol.28, p.7, 2017.

E. Pujade-lauraine, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, Lancet Oncol, vol.18, pp.1274-1284, 2017.

D. Bell, Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, pp.609-615, 2011.